“Directions
Glìalia 700 mg + 70 mg is a food for special medical purposes in microgranules for oral use indicated in subjects with disorders supported by neuroinflammatory processes associated with:
Transient ischemic events (TIA).
Ischemic post-ictal states.
Post-traumatic states of the CNS.
States of cognitive decline (Mild Neurocognitive Disorder – Mild-NCD).
Early stage dementia.
Parkinsonism in the initial phase.
Inflammatory demyelinating diseases.
Motor neuron diseases.
Altered mood states.
The food is based on:
Palmitoylethanolamide, an endogenous natural substance of a lipid nature with an N-acylethanolamide structure, which in the body has the function of intervening physiologically to maintain intersystem tissue homeostasis.
Luteolin, a natural substance belonging to the flavone family, with considerable and peculiar antioxidant effects. The association of Palmitoylethanolamide and Luteolin in co-ultramicronized form (PEALUT ultramicrocomposite) allows the two active ingredients to exert a synergistic effect in the control of neuroinflammation induced by different endogenous and exogenous noxae affecting the Central Nervous System; this control is carried out through the inhibitory modulation of non-neuronal cells – astrocytes, microglia, mast cells – normally responsible for guaranteeing the balance of the central nervous tissue.
Ingredients
Palmitoylethanolamide Co-ultramicronized with Luteolin (particle size 0.8 – 6.0 μm); Adjuvant: Sorbitol;
Co-ultramicronized Luteolin with Palmitoylethanolamide (particle size 0.8 – 6.0 μm): Emulsifiers: Palmitic Sucrose Esters, Vegetable Polysorbate.
Gluten free.”
